Wall Street analysts predict that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will report earnings per share (EPS) of $0.05 for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Pacira Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is $0.02. Pacira Pharmaceuticals posted earnings of ($0.11) per share during the same quarter last year, which suggests a positive year over year growth rate of 145.5%. The company is expected to announce its next quarterly earnings results on Wednesday, August 1st.

On average, analysts expect that Pacira Pharmaceuticals will report full-year earnings of $0.25 per share for the current financial year, with EPS estimates ranging from $0.12 to $0.43. For the next financial year, analysts forecast that the business will post earnings of $0.96 per share, with EPS estimates ranging from ($0.36) to $2.19. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. The business had revenue of $74.61 million for the quarter, compared to analyst estimates of $73.92 million. During the same period in the previous year, the company earned ($0.19) earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year.

PCRX has been the topic of a number of analyst reports. Wedbush dropped their target price on Pacira Pharmaceuticals from $72.00 to $80.00 and set an “outperform” rating on the stock in a research report on Monday, April 9th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $43.00 price target (up from $40.00) on shares of Pacira Pharmaceuticals in a research note on Monday, April 9th. Seaport Global Securities reaffirmed a “buy” rating and issued a $42.00 price target on shares of Pacira Pharmaceuticals in a research note on Tuesday, March 20th. Mizuho dropped their price target on shares of Pacira Pharmaceuticals from $44.00 to $31.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 21st. Finally, Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $45.00.

Shares of Pacira Pharmaceuticals traded down $0.05, reaching $32.85, during midday trading on Tuesday, according to MarketBeat.com. 1,633 shares of the company’s stock were exchanged, compared to its average volume of 802,326. Pacira Pharmaceuticals has a 52-week low of $26.95 and a 52-week high of $51.10. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -56.47 and a beta of 1.79. The company has a debt-to-equity ratio of 1.00, a quick ratio of 7.83 and a current ratio of 8.66.

In other Pacira Pharmaceuticals news, insider Richard Scranton sold 1,367 shares of the company’s stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $33.02, for a total transaction of $45,138.34. Following the completion of the sale, the insider now directly owns 12,226 shares in the company, valued at $403,702.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David M. Stack sold 18,406 shares of the company’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $36.28, for a total transaction of $667,769.68. Following the sale, the chief executive officer now owns 91,831 shares of the company’s stock, valued at $3,331,628.68. The disclosure for this sale can be found here. Insiders have sold 49,093 shares of company stock valued at $1,700,983 over the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE boosted its stake in shares of Pacira Pharmaceuticals by 53.8% in the 1st quarter. US Bancorp DE now owns 4,292 shares of the company’s stock valued at $134,000 after purchasing an additional 1,501 shares during the last quarter. First Republic Investment Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the fourth quarter valued at about $201,000. Twin Focus Capital Partners LLC purchased a new stake in shares of Pacira Pharmaceuticals in the fourth quarter valued at about $206,000. Fisher Asset Management LLC raised its holdings in shares of Pacira Pharmaceuticals by 29.6% in the first quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock valued at $213,000 after purchasing an additional 1,566 shares during the last quarter. Finally, Redmile Group LLC purchased a new stake in shares of Pacira Pharmaceuticals in the fourth quarter valued at about $237,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.